Scarica l'app Stockscreener
2.92
2.67%
-0.08
Precedente Chiudi:
$3.00
Aprire:
$3.0046
Volume 24 ore:
15,315
Relative Volume:
0.43
Capitalizzazione di mercato:
$25.41M
Reddito:
-
Utile/perdita netta:
$-30.16M
Rapporto P/E:
-8.5882
EPS:
-0.34
Flusso di cassa netto:
$-39.49M
1 W Prestazione:
-3.63%
1M Prestazione:
-7.89%
6M Prestazione:
-11.78%
1 anno Prestazione:
+534.37%
Intervallo 1D:
$2.92
$3.02
Intervallo di 1 settimana:
$2.92
$3.0301
Portata 52W:
$0.28
$4.60
Dare Bioscience Inc Stock (DARE) Company Profile
Nome
Dare Bioscience Inc
Settore
Industria
Telefono
858-926-7655
Indirizzo
3655 NOBEL DRIVE, SAN DIEGO, CA
Confronta DARE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.92 | 25.41M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Dare Bioscience, Inc. to Host Earnings Call - ACCESS Newswire
Daré Bioscience and Theramex Announce Co-Development and - GlobeNewswire
Dare Bioscience and Theramex Announce Co-Development and Licensing Agreement for A Potential Biodegradable Long-Acting Contraceptive Implant - Marketscreener.com
Daré, Theramex partner on biodegradable contraceptive implant - Investing.com
Daré, Theramex partner on biodegradable contraceptive implant By Investing.com - Investing.com South Africa
Revolutionary Contraceptive Tech: This New Implant Actually Dissolves After Use - StockTitan
Dare Bioscience risks Nasdaq delisting over market value - MSN
Dare Bioscience (NASDAQ: DARE) Files 8-K with SEC Regarding Corporate Presentation - Defense World
Daré Bioscience to Present at BIO CEO Conference - TipRanks
Dare Bioscience secures additional NIAID funding for HPV treatment - MSN
Dare Bioscience secures additional NIAID funding for HPV treatment By Investing.com - Investing.com Nigeria
Daré Bioscience Announces Funding Award Notice from the - GlobeNewswire
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development - The Manila Times
Revolutionary HPV Treatment Gets $12M Funding Boost: A New Hope for Cervical Health - StockTitan
Daré Bioscience (NASDAQ:DARE) Shares Cross Below 200-Day Moving Average – Time to Sell? - Defense World
Daré Bioscience (NASDAQ:DARE) Prepares to Share Corporate Presentation on January 13, 2025 - Defense World
Geode Capital Management LLC Decreases Stock Holdings in Daré Bioscience, Inc. (NASDAQ:DARE) - Defense World
Daré Bioscience (NASDAQ:DARE) Share Price Crosses Above Fifty Day Moving Average – Time to Sell? - Defense World
Daré Bioscience Announces New Corporate Presentation - TipRanks
Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Daré Bioscience CEO to Spotlight Women's Health Innovation at J.P. Morgan Healthcare Conference - StockTitan
State Street Corp Lowers Stake in Daré Bioscience, Inc. (NASDAQ:DARE) - Defense World
Daré Bioscience, Inc. and ARPA-H Ring the Nasdaq Stock Market Closing Bell - Nasdaq
Daré Bioscience, Inc. and ARPA-H Ring the Closing Bell - Nasdaq
Daré Bioscience (NASDAQ:DARE) Shares Pass Below 200-Day Moving Average – Time to Sell? - Defense World
Daré Bioscience (NASDAQ:DARE) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
DARE Stock Touches 52-Week Low at $3.04 Amid Market Challenges - Investing.com
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream Development to Address Female Sexual Arousal Disorder - Defense World
Daré Bioscience to initiate phase 3 study of FSAD treatment - Investing.com
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) - The Manila Times
Daré Bioscience Announces Phase 3 Plans for Sildenafil - GlobeNewswire
Daré Bioscience Advances First-Ever FSAD Treatment: Phase 3 Trial Set for Breakthrough Female Sexual Health Drug - StockTitan
Daré Bioscience Announces Publication in Sexual Medicine of - GlobeNewswire
Daré Bioscience's Sildenafil Cream Shows Promising Clinical Data for Female Sexual Health Treatment - StockTitan
Daré Bioscience receives $2.5 million for contraceptive tech By Investing.com - Investing.com Canada
Daré Bioscience receives $2.5 million for contraceptive tech - Investing.com India
DAREDare Bioscience, Inc. Latest Stock News & Market Updates - StockTitan
Daré Bioscience Announces $2.5 Million Grant Funding - GlobeNewswire
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 - The Manila Times
Daré Bioscience Advances Revolutionary Wireless Contraceptive Tech With $2.5M Grant Milestone - StockTitan
Dare Bioscience Q3 2024 Earnings Preview - MSN
Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World
Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - MSN
Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know - MSN
Dare Bioscience files to sell 2.75M shares of common stocks by selling shareholders - MSN
Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2024 Earnings Call Transcript - Insider Monkey
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Dare Bioscience Inc Azioni (DARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):